Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

respectively, when compared to the three and nine month periods ended April 30, 2008. The increase in product revenue is the result of higher revenues from the sale of Orthovisc(R) in both the three and nine month periods ended April 30, 2009.

License fees and royalty revenue

License fees and royalties totaled $131,000 and $452,000 respectively for the three and nine month periods ended April 30, 2009 and represent a decrease of $112,000 (46.1%) and $61,000 (11.9%) respectively, when compared to the three and nine month periods ended April 30, 2008. In the first quarter of fiscal 2009 and the third quarter of fiscal 2008, license fees and royalty revenues include a termination payment and royalty revenues from Lumera Corporation totaling US$75,000 and US$100,000, respectively. All other license fees and royalties are comprised solely of royalties related to sales of Klean-Prep(TM) outside of Canada.

Cost of sales and margins

Cost of sales totaled $375,000 and $1,160,000 respectively for the three and nine month periods ended April 30, 2009 (three and nine month periods ended April 30, 2008: $326,000 and $908,000 respectively). Margins, on a percentage basis, for the three and nine month periods ended April 30, 2009 remained flat throughout the year at 52.7% (three and nine month periods ended April 30, 2008: 57.9% and 58.4% respectively). The decrease in margins reflect in part, higher purchase costs resulting from a lower Canadian dollar versus the U.S. dollar and increased competitive pricing and product offering in direct competition with Orthovisc(R).

Research & development

Research & development costs for the three and nine month periods ended April 30, 2009 totaled $3,082,000 and $7,584,000, respectively (three and nine month periods ended April 30, 2008: $1,068,000 and $2,879,000 respectively). Of the increase in research and development expenditure
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 Follow us on ... of the fastest growing technologies in the life sciences ... visualization is driving growth in nucleic acid detection technologies ... of gene expressions will continue to benefit the qPCR ... fields ranging from pharma, biotech, food & beverage to ...
(Date:3/4/2015)... , March 4, 2015 ... de Paris en décembre ...   SARAH   », qui compare   l ... avec le   sorafénib dans le carcinome hépatocellulaire ... d,un cancer du foie avancé   ; les ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... astronaut Scott Kelly , who is making final preparations ... and working on the International Space Station, will be available ... Monday, March 9. Kelly will participate from ... of his training. The interviews will be preceded at 5 ... training and previous spaceflights. To schedule an interview, ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... June 12 Biopure Corporation,(Nasdaq: BPUR ) announced ... an additional 180 days, or until December 8, 2008, ... bid price,of $1.00 for continued listing. Currently, the Company ... Market. If, at any time,before December 8, 2008, the ...
... Chindex International,Inc. (Nasdaq: CHDX ), an independent ... products in the People,s,Republic of China, provided the ... which will be reported in the Company,s Annual ... the Securities and Exchange Commission,on Monday, June 16, ...
... XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) ... Meeting and Extraordinary General,Meeting (collectively, the "Meetings") scheduled for ... record at the close of business on,June 12, 2008 ... the Meetings. All,shareholders are cordially invited to attend the ...
Cached Biology Technology:Biopure Granted Additional 180 Day Compliance Period by NASDAQ 2Chindex International, Inc. Quantifies Fourth Quarter Charges 2Chindex International, Inc. Quantifies Fourth Quarter Charges 3Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting 2
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... handful of very special mice, scientists have discovered a ... implicated in the development of human leukemia, findings that ... study authors say. , Researchers in The Ohio State ... that develops acute lymphoblastic leukemia (ALL). The mouse first ...
... good handle on how to teach human cells to do ... mouth's lining to form bone. , But in the real ... bone of a person undergoing radiation therapy for cancer means ... well as compensating for the damage of radiation. , "It's ...
... involving the buzzword "nano" - cancer detection using nanoparticles ... of cancers is one of the most important parts ... prognosis and determination,of the most appropriate treatment. And an ... not there has been lymphatic spread. Current,methods include surgical ...
Cached Biology News:Genome-wide mouse study yields link to human leukemia 2Genome-wide mouse study yields link to human leukemia 3U-M scientist to talk about tissue engineering at AAAS 2Imaging Lymph Nodes with Nanoparticles 2
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
Biology Products: